MA55490A - Mutéine de lipocaline pour le traitement de l'asthme - Google Patents
Mutéine de lipocaline pour le traitement de l'asthmeInfo
- Publication number
- MA55490A MA55490A MA055490A MA55490A MA55490A MA 55490 A MA55490 A MA 55490A MA 055490 A MA055490 A MA 055490A MA 55490 A MA55490 A MA 55490A MA 55490 A MA55490 A MA 55490A
- Authority
- MA
- Morocco
- Prior art keywords
- asthma
- treatment
- lipocalin mutein
- lipocalin
- mutein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Otolaryngology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962826791P | 2019-03-29 | 2019-03-29 | |
US201962845774P | 2019-05-09 | 2019-05-09 | |
US201962906443P | 2019-09-26 | 2019-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55490A true MA55490A (fr) | 2022-02-09 |
Family
ID=70008540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055490A MA55490A (fr) | 2019-03-29 | 2020-03-25 | Mutéine de lipocaline pour le traitement de l'asthme |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220193191A1 (fr) |
EP (1) | EP3946415A1 (fr) |
JP (1) | JP2022526524A (fr) |
KR (1) | KR20210146934A (fr) |
CN (1) | CN113613669A (fr) |
AU (1) | AU2020252050A1 (fr) |
CA (1) | CA3133422A1 (fr) |
IL (1) | IL286756A (fr) |
MA (1) | MA55490A (fr) |
SG (1) | SG11202109839YA (fr) |
WO (1) | WO2020200960A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022129629A1 (fr) | 2020-12-18 | 2022-06-23 | Astrazeneca Ab | Formulation de poudre sèche de mutéine de la lipocaline pour le traitement de l'asthme |
CN114780621B (zh) * | 2022-06-23 | 2022-10-04 | 中铁电气化勘测设计研究院有限公司 | 一种轨道交通接触网缺陷检索方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
EP1430136A1 (fr) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteines d'apolipoproteine d |
WO2003029462A1 (fr) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees |
WO2005019255A1 (fr) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteines de la lipocaline lacrymale |
EP2899277A1 (fr) | 2004-11-26 | 2015-07-29 | Pieris AG | Composé à affinité pour l'antigène associé aux lymphocytes T cytotoxiques (CTLA-4) |
CA2659413C (fr) | 2006-08-01 | 2016-06-14 | Pieris Ag | Muteines de lipocaline lacrymale et procedes permettant d'obtenir lesdites muteines |
CN105949301B (zh) | 2010-06-08 | 2020-03-27 | 皮里斯制药有限公司 | 结合IL-4受体α的泪脂质运载蛋白突变蛋白 |
DK3453400T3 (da) | 2011-12-13 | 2021-04-06 | Pieris Pharmaceuticals Gmbh | Fremgangsmåder til forebyggelse eller behandling af visse forstyrrelser ved inhibering af binding af il-4 og/eller il-13 til deres respektive receptorer |
-
2020
- 2020-03-25 WO PCT/EP2020/058360 patent/WO2020200960A1/fr unknown
- 2020-03-25 JP JP2021557186A patent/JP2022526524A/ja active Pending
- 2020-03-25 EP EP20714575.6A patent/EP3946415A1/fr active Pending
- 2020-03-25 CN CN202080023518.0A patent/CN113613669A/zh active Pending
- 2020-03-25 CA CA3133422A patent/CA3133422A1/fr active Pending
- 2020-03-25 MA MA055490A patent/MA55490A/fr unknown
- 2020-03-25 US US17/599,034 patent/US20220193191A1/en not_active Abandoned
- 2020-03-25 AU AU2020252050A patent/AU2020252050A1/en not_active Abandoned
- 2020-03-25 SG SG11202109839Y patent/SG11202109839YA/en unknown
- 2020-03-25 KR KR1020217031533A patent/KR20210146934A/ko unknown
-
2021
- 2021-09-29 IL IL286756A patent/IL286756A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113613669A (zh) | 2021-11-05 |
WO2020200960A1 (fr) | 2020-10-08 |
US20220193191A1 (en) | 2022-06-23 |
AU2020252050A1 (en) | 2021-11-11 |
CA3133422A1 (fr) | 2020-10-08 |
EP3946415A1 (fr) | 2022-02-09 |
IL286756A (en) | 2021-10-31 |
SG11202109839YA (en) | 2021-10-28 |
KR20210146934A (ko) | 2021-12-06 |
JP2022526524A (ja) | 2022-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
MA56050A (fr) | Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA51916A (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
MA54609A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA52861A (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
MA50441A (fr) | Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild) | |
MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
MA52961A (fr) | Compositions et procédés pour la réduction ou le traitement d'une inflammation | |
MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
MA52657A (fr) | Anticorps spécifiques d'axl pour le traitement du cancer | |
MA53252A (fr) | Thérapie génique non perturbatrice pour le traitement d'un mma | |
MA51613A (fr) | Polythérapie pour le traitement ou la prévention du cancer | |
MA55490A (fr) | Mutéine de lipocaline pour le traitement de l'asthme | |
MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
MA54559A (fr) | Polythérapie pour le traitement du cancer | |
MA52960A (fr) | Compositions et procédés pour la réduction ou le traitement de la fibrose | |
MA56508A (fr) | Inhibiteur d'egfr pour le traitement du cancer | |
MA54809A (fr) | Composition pharmaceutique comprenant du macitentan pour le traitement de l'hypertension pulmonaire thromboembolique chronique |